Chiasma, Inc., a U.S. privately–held biopharma company developing octreotide capsules for the orphan condition acromegaly, today announced two new studies presented at the 97th Endocrine Society (ENDO) Annual Meeting in San Diego, Calif. The studies provide additional data from Chiasma’s Phase III trial and new findings on the patient burden of current injection therapies.
“We now have data to help clinicians determine whether octreotide capsules, if approved, are likely to help their patient with acromegaly maintain response,” said Shlomo Melmed, M.D., senior vice president and dean, Cedars–Sinai Medical Center, Los Angeles and global study principal investigator. “Furthermore, the Phase III results show the safety and efficacy of octreotide capsules can be reliably determined within 12 weeks of initiating therapy.”
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7436451-endo-chiasma-clinical-data/
Live Looping with an RC- 300, GR-20, Digitech Jamman, phase shifter, ambient reverb, tera echo, and a Boss Digital Delay. The RC - 300 is used to loop guitar all on separate loops/tracks, the pedals are used to create ambient and delayed sounds with the guitar.
Video by HouseTwelve Media (http://www.housetwelve.com/)
The sixth annual Productive Innovation Index released by IDEA Pharma today, which ranks biopharmaceutical companies by their ability to successfully bring innovations to market, sees Johnson & Johnson top the industry for the fourth year running.
The Productive Innovation Index measures, scores and celebrates a company’s ability to deliver innovation to patients, by objectively evaluating performance data based on a rolling five year period (2010-2015), and operates on the premise: if you gave the same molecule to two different companies in early phase, which would make the best of it?
The success of the Janssen Pharmaceutical Companies of Johnson & Johnson and its consolidation of 1st place across the past four years’ rankings is driven largely by innovations in the field of oncology, immunology, neuroscience and cardiovascular/metabolism. Notable performers include Zytiga® (prostate cancer), Imbruvica® (chronic lymphocytic leukemia and mantle cell lymphoma (co-developed and co-marketed with Pharmacyclics, an AbbVie company)), Simponi®/Simponi Aria® (rheumatoid arthritis), Stelara® (psoriasis and psoriatic arthritis), Invega Sustenna® and Invega Trinza® (schizophrenia).
To view the multimedia release go to:
http://www.multivu.com/players/uk/7770851-johnson-and-johnson-tops-idea-pharma/
Today, Novo Nordisk announced new phase 3 interim data from its guardianTM2 trial for its recombinant coagulation factor VIII (rFVIII) product NovoEight® (turoctocog alfa), the first new rFVIII molecule in over a decade, which shows that it provides long-term reduction from bleeding in people with haemophilia A when used as a preventative treatment.1 The results were presented at the World Federation of Haemophilia (WFH) World Congress and support findings from other studies within the guardianTM clinical programme that found NovoEight® demonstrated good efficacy in preventing and treating bleeds without inhibitor development in previously treated patients.
To view the Multimedia News Release, go to: http://www.multivu.com/mnr/71400529-novoeight-reduction-of-bleeding-haemophilia-a
Volvo Cars and Swedish artist & producer Avicii announce a creative cooperation to celebrate their Swedish roots with a new recording and music video, due for global release on May 8th. The collaboration will form the basis for a global brand campaign entitled ‘A New Beginning’.
Stockholm-born Avicii, 25, has made a huge impact in the world of music in recent years, and is renowned for being one of the world’s top DJs, remixers and record producers. With a shared Swedish heritage, Volvo Cars and Avicii are now both entering a new phase in their existence.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7506451-volvo-avicii-a-new-beginning/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
GW Pharmaceuticals plc (Nasdaq: GWPH, “GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The New England Journal of Medicine has published results from a Phase 3 study of Epidiolex® (cannabidiol) in children with Dravet syndrome.1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs, is a liquid formulation of purified, plant-derived cannabidiol (CBD), a non-psychoactive cannabinoid, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In the study, Epidiolex significantly reduced monthly convulsive seizure frequency compared to placebo in highly treatment-resistant children when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior open label experience.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8109951-gw-pharmaceuticals-study-epidiolex/
A “strategy-to-execution gap” plaguing corporations around the globe could lead companies to lose 50 percent of their potential cumulative cash flow on new growth investments if not properly addressed, according to CEB (NYSE: CEB), the leading member-based advisory company. That is because most new growth strategies lose value during the implementation phase, with at least one-in-three strategic initiatives failing altogether.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7082252-ceb-executive-guidance-for-2015-closing-strategy-to-execution-gaps/
Nexity, un des leader du marché de l’administration de biens, veut faire émerger des bonnes pratiques et transformer les métiers de services immobiliers aux particuliers. Nexity veut aussi répondre toujours mieux à ses clients propriétaires bailleurs avec des services qui correspondent vraiment à leurs besoins, en phase avec leur mode de vie de plus en plus connecté et mobile. D’où l’idée de leur proposer une nouvelle approche du mandat de gestion locative, 100% en ligne et à un coût particulièrement compétitif !
Beaucoup plus que la simple possibilité pour nos clients de pouvoir consulter en ligne les mouvements comptables correspondant à des mandats traditionnels, e-gérance leur permet, directement en ligne et en trois clics, de confier la responsabilité comptable, administrative et réglementaire à un mandataire expert. Tout en conservant la relation avec leur locataire et la gestion patrimoniale de leur bien.
To view the multimedia release go to:
http://www.multivu.com/players/fr/7747651-nexity-lance-e-gerance-gestion-locative/
West Pharmaceutical Services, Inc. (NYSE: WST) and HealthPrize Technologies, LLC, today announced the completion of the first two phases of their four-phase strategic collaboration. The companies are working to integrate HealthPrize’s Software-as-a-Service (SaaS) medication adherence and patient-engagement platform with West’s injectable drug delivery systems to provide an end-to-end connected health solution for pharmaceutical companies and the patients they serve. The combined offering will provide voluntary, electronically connected drug delivery systems that track when patients take their medication. The HealthPrize system engages and educates patients to increase adherence and medical literacy, rewarding interaction and compliance with prescribed treatment plans, and contributing to better health outcomes.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7625851-west-pharma-healthprize-tech-collaboration/
Volvo Cars today declares an end to a problem faced daily by drivers around the globe: a lack of suitable and functional storage space inside their car. With its innovative approach inside the new XC40 small city SUV, set to be launched in the coming weeks, Volvo Cars takes the lead in the small premium SUV segment in terms of space, storage and all-round functionality.
The highly anticipated XC40 from Volvo Cars will complete the company’s SUV line-up that also features the top-of-the-range large XC90 and the mid-sized XC60.
As part of the XC40’s development phase, Volvo Cars’ customer research team spent considerable time investigating how city dwellers around the globe use their car on a daily basis – and, more importantly, how they store their belongings in their cars. Customers were also asked how they would like to see the interiors of their cars improved.
To view the multimedia release go to:
https://www.multivu.com/players/uk/8163951-end-clutter-volvo-cars-XC40-small-SUV/
Global biotherapeutics leader CSL Behring today announced that results were published in the New England Journal of Medicine (NEJM) from the COMPACT study, a pivotal Phase III study evaluating the safety and efficacy of CSL830 (a novel, investigational, self-administered, subcutaneous C1-Esterase Inhibitor [C1-INH] Human replacement therapy) for the prevention of HAE attacks. The study met its primary efficacy endpoint, significantly reducing the time-normalized number of HAE attacks. In addition, the study met its secondary endpoints, including the responder rate (patients who had at least a 50% reduction in their attack rate) and the number of rescue medication uses. If approved by the FDA, CSL830 would be the first and only subcutaneous preventative therapy for HAE.
To view the multimedia release go to:
https://www.multivu.com/players/English/8056151-csl-behring-subcutaneous-c1-esterase-inhibitor-hae-patients/
